Analysts' ratings for ACADIA Pharmaceuticals ACAD over the last quarter vary from bullish to bearish, as provided by 13 analysts.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 5 | 3 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 2 | 2 | 2 | 0 | 0 |
| 2M Ago | 1 | 2 | 1 | 0 | 0 |
| 3M Ago | 1 | 1 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for ACADIA Pharmaceuticals, presenting an average target of $34.08, a high estimate of $42.00, and a low estimate of $25.00. Observing a 13.15% increase, the current average has risen from the previous average price target of $30.12.
Understanding Analyst Ratings: A Comprehensive Breakdown
The standing of ACADIA Pharmaceuticals among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Uy Ear | Mizuho | Raises | Buy | $40.00 | $35.00 |
| Jeffrey Hung | Morgan Stanley | Raises | Overweight | $40.00 | $31.00 |
| Paul Matteis | Stifel | Raises | Hold | $27.00 | $25.00 |
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $42.00 | - |
| Neena Bitritto-Garg | Deutsche Bank | Announces | Hold | $25.00 | - |
| David Hoang | Citigroup | Announces | Buy | $38.00 | - |
| Neena Bitritto-Garg | Deutsche Bank | Announces | Buy | $25.00 | - |
| Uy Ear | Mizuho | Raises | Buy | $35.00 | $20.00 |
| Jason Butler | JMP Securities | Raises | Market Outperform | $42.00 | $39.00 |
| Gregory Renza | RBC Capital | Raises | Outperform | $33.00 | $32.00 |
| Jeffrey Hung | Morgan Stanley | Raises | Equal-Weight | $31.00 | $30.00 |
| Ashwani Verma | UBS | Announces | Buy | $33.00 | - |
| Tessa Romero | JP Morgan | Raises | Overweight | $32.00 | $29.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to ACADIA Pharmaceuticals. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of ACADIA Pharmaceuticals compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for ACADIA Pharmaceuticals's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
To gain a panoramic view of ACADIA Pharmaceuticals's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on ACADIA Pharmaceuticals analyst ratings.
Get to Know ACADIA Pharmaceuticals Better
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Understanding the Numbers: ACADIA Pharmaceuticals's Finances
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Positive Revenue Trend: Examining ACADIA Pharmaceuticals's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 61.96% as of 30 September, 2023, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: ACADIA Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of -30.79%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): ACADIA Pharmaceuticals's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -17.2% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): ACADIA Pharmaceuticals's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -10.22%, the company may face hurdles in achieving optimal financial returns.
Debt Management: ACADIA Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.16.
The Significance of Analyst Ratings Explained
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
